Foghorn Therapeutics (FHTX) Consolidated Net Income (2019 - 2026)

Foghorn Therapeutics' Consolidated Net Income history runs 8 years deep, the most recent figure standing at -$19.8 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 1.93% year-over-year to -$19.8 million; the TTM figure through Mar 2026 stood at -$77.3 million (up 5.59% YoY), while the FY2025 annual figure was -$77.6 million, up 10.36% from the prior year.
• Consolidated Net Income was -$19.8 million for Q1 2026 at Foghorn Therapeutics, up from -$22.2 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$14.3 million in Q3 2023 to a low of -$30.5 million in Q1 2023.
• Historically, Consolidated Net Income has averaged -$23.0 million across 5 years, with a median of -$23.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Consolidated Net Income surged 44.33% in 2023, then sank 33.3% in 2024.
• A 5-year view of Consolidated Net Income shows it stood at -$28.9 million in 2022, then grew by 16.55% to -$24.1 million in 2023, then climbed by 19.09% to -$19.5 million in 2024, then decreased by 13.65% to -$22.2 million in 2025, then climbed by 10.53% to -$19.8 million in 2026.
• The last three Consolidated Net Income figures came in at -$19.8 million (Q1 2026), -$22.2 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.